FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tobias Wirenfeldt Klausen

Research Profile

Disorders

Geographic Areas

Denmark

Genes & Molecular Sequences

Single Nucleotide Polymorphism

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nina Toft; Goda Vaitkeviciene; Kim Vettenranta; Mervi Taskinen; Jonas Abrahamsson; Ann Asberg; Per Bernell; Henrik Birgens; Laimonas Griškevičius; Helene Hallböök; Mats Heyman; Mette Skov Holm; Erik Hulegårdh; Olafur Gísli Jónsson; Tobias Wirenfeldt Klausen; Hanne V Marquart; Ove Juul Nielsen; Petter Quist-Paulsen; Kjeld Schmiegelow
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Shamaila Munir; Inge Marie Svane; Özcan Met; Gitte Holmen Andersen; Marco Donia; Thomas Mørch Frøsig; Tobias Wirenfeldt Klausen; SK Larsen; Mads Hald Andersen
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.
Sif Gudbrandsdottir; Henrik Birgens; Henrik Frederiksen; Bjarne Anker Jensen; Morten Krogh Jensen; Lars Kjeldsen; Tobias Wirenfeldt Klausen; Herdis Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Ove Juul Nielsen; Torben Plesner; Stanislaw Pulczynski; Inge Helleberg Rasmussen; Dorthe Rønnov-Jessen; Hans Carl Hasselbalch
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tobias Wirenfeldt Klausen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nina Toft; Goda Vaitkeviciene; Kim Vettenranta; Mervi Taskinen; Jonas Abrahamsson; Ann Asberg; Per Bernell; Henrik Birgens; Laimonas Griškevičius; Helene Hallböök; Mats Heyman; Mette Skov Holm; Erik Hulegårdh; Olafur Gísli Jónsson; Tobias Wirenfeldt Klausen; Hanne V Marquart; Ove Juul Nielsen; Petter Quist-Paulsen; Kjeld Schmiegelow
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
European journal of haematology 2013;90(5):404-12.
2013: Shamaila Munir; Inge Marie Svane; Özcan Met; Gitte Holmen Andersen; Marco Donia; Thomas Mørch Frøsig; Tobias Wirenfeldt Klausen; SK Larsen; Mads Hald Andersen
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.
Cancer research 2013;73(6):1764-76.
2013: Sif Gudbrandsdottir; Henrik Birgens; Henrik Frederiksen; Bjarne Anker Jensen; Morten Krogh Jensen; Lars Kjeldsen; Tobias Wirenfeldt Klausen; Herdis Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Ove Juul Nielsen; Torben Plesner; Stanislaw Pulczynski; Inge Helleberg Rasmussen; Dorthe Rønnov-Jessen; Hans Carl Hasselbalch
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
Blood 2013;121(11):1976-81.
2012: Niels Frost Andersen; Peter Gimsing; Henrik Gregersen; Tobias Wirenfeldt Klausen; Niels Abildgaard; Ulla Vogel; Annette J Vangsted
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
International journal of cancer. Journal international du cancer 2012;131(5):E636-42.
2012: Annette J Vangsted; Einar Haukaas; Tobias Wirenfeldt Klausen; Kaspar R Nielsen; Anne Tjønneland; Ulla Vogel
A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.
British journal of haematology 2012;158(4):515-8.
2012: Marianne Hutchings Hoffmann; Olav J Bergmann; Martin Boegsted; Karen Dybkaer; Henrik Hasle; Tobias Wirenfeldt Klausen; Steffen Falgreen Larsen; Eva Birgitte Leinoe; Mette Nyegaard; Kjeld Schmiegelow; Alexander Schmitz; Suzette Sorensen; Hans E Johnsen
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Cytometry. Part B, Clinical cytometry 2012;82(3):123-31.
2012: Heidi M Christensen; Jens Faber; Allan Flyvbjerg; Jan Frystyk; Per Hildebrandt; Tobias Wirenfeldt Klausen; Ilan Raymond; Morten Schou; Caroline Kistorp
α-Defensins and outcome in patients with chronic heart failure.
European journal of heart failure 2012;14(4):387-94.
2012: Nina Toft; Tobias Wirenfeldt Klausen; Kjeld Schmiegelow; Henrik Birgens
Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008.
British journal of haematology 2012;157(1):97-104.
2012: Annette Vangsted; Tobias Wirenfeldt Klausen; Ulla Vogel
Genetic variations in multiple myeloma II: association with effect of treatment.
European journal of haematology 2012;88(2):93-117.
2012: Shamaila Munir; Per thor Straten; Inge Marie Svane; Marco Donia; Trine Zeeberg Iversen; Tobias Wirenfeldt Klausen; SK Larsen; Mads Hald Andersen
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
PloS one 2012;7(4):e34568.
2012: Annette Vangsted; Tobias Wirenfeldt Klausen; Ulla Vogel
Genetic variations in multiple myeloma I: effect on risk of multiple myeloma.
European journal of haematology 2012;88(1):8-30.
2011: Annette J Vangsted; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Tobias Wirenfeldt Klausen; Bjørn A Nexø; Ulla Vogel
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Annals of hematology 2011;90(10):1173-81.
2011: Annette J Vangsted; Tobias Wirenfeldt Klausen; Peter Gimsing; Niels Abildgaard; Niels F Andersen; Henrik Gregersen; Bjørn Andersen Nexø; Ulla Birgitte Vogel
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.
Annals of hematology 2011;90(6):675-84.
2011: Lene Boesby; Thomas Elung-Jensen; Tobias Wirenfeldt Klausen; Svend Strandgaard; Anne-Lise Kamper
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
PloS one 2011;6(11):e26904.
2010: Hans E Johnsen; Martin Bøgsted; Tobias Wirenfeldt Klausen; Peter Gimsing; Alexander Schmitz; Erik Kjaersgaard; Tina Damgaard; Pia Voss; Lene Meldgaard Knudsen; Anne K Mylin; Johan Lanng Nielsen; Bo Björkstrand; Astrid Gruber; Stig Lenhoff; Kari Remes; Inger Marie S Dahl; Kirsten Fogd; Karen Dybkaer
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.
Cytometry. Part B, Clinical cytometry 2010;78(5):338-47.
2010: Annette J Vangsted; Tobias Wirenfeldt Klausen; Niels F Andersen; Niels Abildgaard; Anne O Gang; Henrik Gregersen; Ulla Vogel; Peter Gimsing
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004.
European journal of haematology 2010;85(3):209-16.
2010: Hans E Johnsen; Tobias Wirenfeldt Klausen; Martin Boegsted; Stig Lenhoff; Peter Gimsing; Ilse Christiansen; Tobias Gedde-Dahl; Roald Lindås; Ulf-Henrik Mellqvist
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
Clinical lymphoma, myeloma & leukemia 2010;10(4):290-6.
2010: Peter Oluf Andersen; Michael Kammer Jensen; Anne Lippert; Doris ØStergaard; Tobias Wirenfeldt Klausen
Development of a formative assessment tool for measurement of performance in multi-professional resuscitation teams.
Resuscitation 2010;81(6):703-11.
2010: Annette J Vangsted; Karen Søeby; Tobias Wirenfeldt Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Ulla Vogel; Thomas Werge; Henrik B Rasmussen
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
BMC cancer 2010;10():404.
2009: Lone Fuhrmann; Anders Perner; Tobias Wirenfeldt Klausen; Doris Østergaard; Anne Lippert
The effect of multi-professional education on the recognition and outcome of patients at risk on general wards.
Resuscitation 2009;80(12):1357-60.
2009: Caroline H Riley; Kirsten Nikolajsen; Erik Kjaersgaard; Tobias Wirenfeldt Klausen; Torben Mourits-Andersen; Niels Clausen; Birgitte Lausen; Steen Rosthøj; Henrik Birgens
[Flowcytometric diagnostics of hereditary spherocytosis].
Ugeskrift for laeger 2009;171(49):3610-4.
2009: Annette J Vangsted; Tobias Wirenfeldt Klausen; Peter Gimsing; Niels F Andersen; Niels Abildgaard; Henrik Gregersen; Ulla Vogel
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
Haematologica 2009;94(9):1274-81.
2009: A J Vangsted; Tobias Wirenfeldt Klausen; W Ruminski; P Gimsing; N F Andersen; A O Gang; N Abildgaard; L M Knudsen; J L Nielsen; H Gregersen; U Vogel
The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Bone marrow transplantation 2009;43(7):539-45.
2007: Annette Vangsted; Peter Gimsing; Tobias Wirenfeldt Klausen; Bjørn A Nexø; Håkan Wallin; Pernille Andersen; Peter Hokland; Søren Lillevang; Ulla Vogel
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation.
International journal of cancer. Journal international du cancer 2007;120(5):1036-45.
2006: Claudia Schöllkopf; Lars Kjeldsen; Ole Weiss Bjerrum; Hans Torben Mourits-Andersen; Johan Lanng Nielsen; Bjarne Egelund Christensen; Bjarne Anker Jensen; Bjarne Bach Pedersen; Ellen Taaning; Tobias Wirenfeldt Klausen; Henrik Birgens
Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.
Leukemia & lymphoma 2006;47(2):253-60.
2005: Olav J Bergmann; Julia S Johansen; Tobias Wirenfeldt Klausen; Anne K Mylin; Jørgen S Kristensen; Eigil Kjeldsen; Hans E Johnsen
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8644-52.
2005: Lars Møller Pedersen; Tobias Wirenfeldt Klausen; Ulla Høy Davidsen; Hans E Johnsen
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Annals of hematology 2005;84(8):510-6.
2005: Eva Birgitte Leinoe; Marianne Hutchings Hoffmann; Erik Kjaersgaard; Joern Dalsgaard Nielsen; Olav Jonas Bergmann; Tobias Wirenfeldt Klausen; Hans E Johnsen
Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function.
British journal of haematology 2005;128(4):526-32.